The Journal of pediatrics
-
The Journal of pediatrics · Apr 2011
Randomized Controlled Trial Multicenter StudyInfliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
To test the hypothesis that first re-treatment with infliximab, compared with intravenous immunoglobulin (IVIG), might improve outcomes in IVIG-resistant Kawasaki disease. ⋯ In our retrospective study, patients with IVIG-resistant Kawasaki disease whose first re-treatment was with infliximab, compared with IVIG, had faster resolution of fever and fewer days of hospitalization. Coronary artery outcomes and adverse events were similar; the power of the study was limited.